As part of its centenary celebrations, the Institut Pasteur de Dakar and International AIDS Vaccine Initiative (IAVI) a non-profit scientific research organization, signed a historic agreement on December 13, 2024, formalizing their collaboration to develop, manufacture, and ensure access to vaccines in Africa. This agreement marks a significant step in the fight against global health threats, particularly those that disproportionately affect Africa.
Through this partnership, the two organizations will leverage their complementary strengths to create an innovative and sustainable model for vaccine production in Africa, focusing on priority pathogens such as the Lassa virus. The collaboration aims to accelerate the manufacturing of flexible, low-cost vaccines, while supporting Africa’s vaccine manufacturing agenda and global pandemic preparedness.
IAVI, a leader in vaccine research with its rVSV program, will bring its expertise, while IPD, a major player in vaccine production and epidemic response in Africa, will strengthen the continent’s capacity to produce vaccines against emerging threats.
This strategic partnership marks a significant advancement in improving Africa’s health sovereignty and addressing the continent’s public health priorities.
ENG
FR
